NRIX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 105048 min ago

@ $9.02

Wydano: 14 vas. 2024 @ 21:04

Zwrot: 37.03%

Poprzedni sygnał: vas. 14 - 16:30

Poprzedni sygnał: Sprzedaż

Zwrot: 0.89 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders...

Stats
Dzisiejszy wolumen	599 462
Średni wolumen	1.02M
Kapitalizacja rynkowa	733.16M
EPS	$0 ( 2024-04-11 )
Następna data zysków	( $-0.720 ) 2024-07-11
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.65
ATR14	$0.0200 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-16	Van Houte Hans	Sell	6 812	Common Stock
2024-02-13	Van Houte Hans	Buy	150 000	Employee Stock Option (right to buy)
2024-02-13	Van Houte Hans	Buy	45 000	Restricted Stock Units
2024-02-13	Ring Christine	Buy	150 000	Employee Stock Option (right to buy)
2024-02-13	Ring Christine	Buy	45 000	Restricted Stock Units

INSIDER POWER
91.86
Last 100 transactions
Buy: 2 499 418 \| Sell: 108 263

Wolumen Korelacja

Długi: -0.44 (neutral)

Krótki: 0.37 (neutral)

Signal:(51.965) Neutral

Nurix Therapeutics, Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nurix Therapeutics, Inc. Korelacja - Waluta/Towar

-0.17
( neutral )

-0.20
( neutral )

0.00
( neutral )

-0.36
( neutral )

-0.10
( neutral )

-0.06
( neutral )

Nurix Therapeutics, Inc. Finanse

Annual	2023
Przychody:	$76.99M
Zysk brutto:	$63.33M (82.26 %)
EPS:	$-2.65

FY	2023
Przychody:	$76.99M
Zysk brutto:	$63.33M (82.26 %)
EPS:	$-2.65

FY	2022
Przychody:	$38.63M
Zysk brutto:	$27.82M (72.02 %)
EPS:	$-3.42

FY	2021
Przychody:	$29.75M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-2.64

Financial Reports:

No articles found.

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.